Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide - Gilead Sciences

Drug Profile

Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide - Gilead Sciences

Alternative Names: Cobicistat/elvitegravir/emtricitabine/TAF; Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Emtricitabine/cobicistat/elvitegravir/tenofovir alafenamide; Genvoya; Tenofovir alafenamide/cobicistat/elvitegravir/emtricitabine; Tenofovir-alafenamide/elvitegravir/emtricitabine/cobicistat

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gilead Sciences
  • Class Antiretrovirals; Deoxyribonucleosides; Purines; Pyrimidine nucleosides; Quinolones; Small molecules
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; HIV integrase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 09 Nov 2017 Preregistration for HIV-1 infections (In adolescents, In children, In adults, Treatment-experienced) in European Union prior to November 2017 (PO)
  • 09 Nov 2017 The Committee for Medicinal Products for Human Use recommends approval of Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide for HIV-1 infections (In adolescents, In children, In adults, Treatment-experienced) in European Union (PO) (3286254; 9227689)
  • 23 Oct 2017 Gilead Sciences completes a phase II/III trial in HIV-1 infections (In adolescents, Treatment-experienced) in South Africa and USA (PO) (NCT02276612)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top